Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis
ABSTRACT Non‐small cell lung cancer (NSCLC) is often intrinsically resistant to several first‐ and second‐line therapeutics and can rapidly acquire further resistance after a patient begins treatment. Treatment outcomes are, therefore, significantly impacted by the optimization of scheduling. Previo...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wiley
2025-10-01
|
| Rangatū: | CPT: Pharmacometrics & Systems Pharmacology |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1002/psp4.70079 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|